Does dimerisation produce a resolvable peak on a C18 column, or does it co-elute?

Setup, so nobody has to ask: dimerisation · a C18 column.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

Is the standard explanation correct, and if so, what is the evidence for it?

System suitability is the part of a report that tells you whether the method was under control on the day you were tested, and its absence is concerning.

System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

Peptide impurities from solid-phase synthesis include deletion sequences, truncations from premature cleavage, racemised residues from epimerisation and oxidised variants, each of which may have different chromatographic behaviour.

Ask for the chromatogram and the system suitability data, not just the number.

Start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

In practice, temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

The most important parameter is the one that is almost never specified: the gradient slope during the region where your main peak elutes.

Detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.

Formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.

The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.

One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

edited 13 Apr 2026 by shear_at_the_front — added a caveat about sampling

Put another way, coupling the chromatography to mass spectrometry adds identity information but trades chromatographic quality for ionisation efficiency.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

The resolving power of a separation is quantified by the resolution parameter R, defined from the heights and widths of adjacent peaks, and pharmacopoeial methods typically demand R greater than 1.5 for a method to be considered validated.

The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

In practice, the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Inter-laboratory studies using identical methods on identical material show precision well within half a per cent when the method is locked down, pointing to method variability as the primary source of disagreement.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.